Drugs / BAT1306
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03638297 | Aug 2018 → Aug 2022 | colorectal cancer | Sun Yat-sen University | Unknown | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04151329 Background | Jun 2019 → Dec 2020 | cancer | Bio-Thera Solutions | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT1306 | “BAT1306 100mg /pembrolizumab 200mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks” NCT03638297 ↗ |
| Route | Intravenous | “200mg IV infusions” NCT04151329 ↗ |